Last reviewed · How we verify
Firmagon (degarelix)
Firmagon (generic name: degarelix) is a Gonadotropin Releasing Hormone Receptor Antagonist drug developed by Ferring. It is currently FDA-approved (first approved 2008) for Advanced Prostatic Carcinoma.
Firmagon works by blocking the action of gonadotropin-releasing hormone on the pituitary gland, which reduces testosterone production.
Firmagon (degarelix) is a small molecule gonadotropin-releasing hormone receptor antagonist developed by FERRING and currently owned by Ferring. It targets the gonadotropin-releasing hormone receptor to treat advanced prostatic carcinoma. Firmagon was FDA approved in 2008 and is still a patented product. Key safety considerations include its potential to cause injection site reactions and changes in liver function. It has a half-life of 18.6 hours.
At a glance
| Generic name | degarelix |
|---|---|
| Sponsor | Ferring |
| Drug class | Gonadotropin Releasing Hormone Receptor Antagonist |
| Target | Gonadotropin-releasing hormone receptor |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 2008 |
Mechanism of action
Think of it like a lock and key. Gonadotropin-releasing hormone is the key that unlocks the pituitary gland to produce testosterone. Firmagon is a key that blocks the lock, preventing the hormone from working and reducing testosterone levels.
Approved indications
- Advanced Prostatic Carcinoma
Common side effects
- Prostatic specific antigen increased
- Injection site erythema
- Injection site pain
- Injection site induration
- Injection site swelling
- Product storage error
- Hot flush
- Interstitial lung disease
- Osteonecrosis of jaw
- Injection site cellulitis
- Injection site mass
- Injection site nodule
Drug interactions
- High Risk QT Prolonging Agents
Key clinical trials
- A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer (PHASE1,PHASE2)
- Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (PHASE2,PHASE3)
- Radiotherapy After Prostatectomy for Node Positive Prostate Cancer (PHASE3)
- A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer (PHASE2)
- Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response (PHASE2)
- NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. (PHASE1)
- Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer (PHASE3)
- Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT (PHASE2)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Firmagon CI brief — competitive landscape report
- Firmagon updates RSS · CI watch RSS
- Ferring portfolio CI
Frequently asked questions about Firmagon
What is Firmagon?
How does Firmagon work?
What is Firmagon used for?
Who makes Firmagon?
What is the generic name of Firmagon?
What drug class is Firmagon in?
When was Firmagon approved?
What development phase is Firmagon in?
What are the side effects of Firmagon?
What does Firmagon target?
Related
- Drug class: All Gonadotropin Releasing Hormone Receptor Antagonist drugs
- Target: All drugs targeting Gonadotropin-releasing hormone receptor
- Manufacturer: Ferring — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Advanced Prostatic Carcinoma
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing